Related references
Note: Only part of the references are listed.Second cancers in MPN: Survival analysis from an international study
Monia Marchetti et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study
Valerio De Stefano et al.
BLOOD (2020)
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
Francesca Palandri et al.
CANCER (2020)
Therapy-associated leukemic transformation in myeloproliferative neoplasms - What do we know?
Danielle Cuthbert et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options
Alessandra Iurlo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study
Tiziano Barbui et al.
LEUKEMIA (2019)
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
Barbara Mora et al.
CANCER MEDICINE (2019)
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
Elena Maria Elli et al.
FRONTIERS IN ONCOLOGY (2019)
Arterial thromboembolic events preceding the diagnosis of cancer in older persons
Babak B. Navi et al.
BLOOD (2019)
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis
Martina Barone et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms
Junshik Hong et al.
BLOOD ADVANCES (2019)
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients
Margherita Maffioli et al.
BLOOD ADVANCES (2019)
Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
Edit Porpaczy et al.
BLOOD (2018)
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
Nicola Polverelli et al.
HEMATOLOGICAL ONCOLOGY (2018)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
Paola Guglielmelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients
Anna Ravn Landtblom et al.
LEUKEMIA (2018)
Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data
Arianna Ghirardi et al.
BLOOD CANCER JOURNAL (2018)
Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in Sweden
Subhayan Chattopadhyay et al.
LANCET HAEMATOLOGY (2018)
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
J. Grinfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients
Nicola Polverelli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Risk of Second Primary Malignancies in Lung Cancer Survivors - The Influence of Different Treatments
Vincent Yi-Fong Su et al.
TARGETED ONCOLOGY (2017)
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia
Gabriele Gugliotta et al.
HAEMATOLOGICA (2017)
Inflammation and myeloproliferative neoplasms
Federico Lussana et al.
JOURNAL OF AUTOIMMUNITY (2017)
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH
A. Delluc et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
Francesco Passamonti et al.
LANCET ONCOLOGY (2017)
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis (vol 30, pg 1701, 2016)
C. N. Harrison et al.
LEUKEMIA (2017)
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
F. Passamonti et al.
LEUKEMIA (2017)
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
Francesca Palandri et al.
ONCOTARGET (2017)
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia
Gabriele Gugliotta et al.
HAEMATOLOGICA (2017)
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis
Marco Romano et al.
ONCOIMMUNOLOGY (2017)
Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism A Systematic Review and Meta-analysis of Individual Patient Data
Nick van Es et al.
ANNALS OF INTERNAL MEDICINE (2017)
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
Kate J. Newberry et al.
BLOOD (2017)
Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer registry data
Sarah E. R. Bailey et al.
BRITISH JOURNAL OF GENERAL PRACTICE (2017)
Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera
Montse Gomez et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Risk of Second Primary Malignancies Among Cancer Survivors in the United States, 1992 Through 2008
Nicholas Donin et al.
CANCER (2016)
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
Haifa Kathrin Al-Ali et al.
HAEMATOLOGICA (2016)
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
Haifa Kathrin Al-Ali et al.
HAEMATOLOGICA (2016)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome
Lucia Masarova et al.
LEUKEMIA RESEARCH (2015)
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
S. Cerquozzi et al.
BLOOD CANCER JOURNAL (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis
Helna Pettersson et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi et al.
BLOOD (2014)
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Ayalew Tefferi et al.
BLOOD (2013)
Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
Hans Carl Hasselbalch
LEUKEMIA RESEARCH (2013)
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN
Elisabetta Antonioli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Enigmatic sex disparities in cancer incidence
Gustaf Edgren et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2012)
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Robyn M. Emanuel et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Gender Differences in Cancer Susceptibility: An Inadequately Addressed Issue
M. Tevfik Dorak et al.
Frontiers in Genetics (2012)
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies
Dushyant Verma et al.
BLOOD (2011)
Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study
Henrik Frederiksen et al.
BLOOD (2011)
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population
Camilla Nielsen et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
Magnus Bjorkholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis
Francesco Passamonti et al.
BLOOD (2010)
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy
Francesca Palandri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
Alessandro M. Vannucchi et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience
Francesca Palandri et al.
LEUKEMIA & LYMPHOMA (2009)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
G. Barosi et al.
LEUKEMIA (2008)
Leukemic transformation of polycythemia vera - A single center study of 23 patients
F Passamonti et al.
CANCER (2005)
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
G Finazzi et al.
BLOOD (2005)
Share Paper
